Tabletop Fire Pit Lawsuit

198 results
Two additional testosterone trials are scheduled to begin in January as the pace of the bellwether program begins to ramp up over claims of heart attacks, deep vein thrombosis and pulmonary embolism injuries.
A settlement status conference for AndroGel litigation is scheduled for November 2 following two massive verdicts against the manufacturer involve claims that the testosterone gel causes heart attacks and strokes.
The first Testim testosterone gel lawsuit to go to trial will begin next month, with some stringent time limitations set by the federal judge overseeing the claims.
After experiencing a heart attack on Androgel, a Tennessee man has been awarded $140 million, including a massive punitive damage award designed to punish the drug maker for recklessly disregarding the health of consumers. With more than 6,500 similar testosterone drug lawsuits pending in the federal court system, the trial provides a clear signal of how juries may respond to similar evidence and testimony that will be repeated throughout the litigation.
A man awarded $150 million in punitive damages after suffering a testosterone heart attack is calling for a judge to grant him compensatory damages in case the unusual punitive damages-only award is overturned.
AbbVie has been ordered to pay $150 million in punitive damages to a man who suffered a heart attack after four years of AndroGel use in the first complete testosterone bellwether trial.
Two Axiron lawsuits have been selected to serve as bellwether trials starting in January 2018, as bellwether trials for AndroGel cases are currently underway.
Notifications